Clinical Trial Update: Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of iobenguane I-131 (MIBG) in patients with malignant pheochromocytoma or paraganglioma completed; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Iobenguane I-131 (iobenguane I-131)

Snippet

Sponsor: Molecular Insight Pharmaceuticals, Inc. | Conditions: Pheochromocytoma, Paraganglioma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-04-20